Floatz logo

Ravuconazole

Chronic Myeloproliferative Disorders

National Institutes of Health Clinical Center (CC)Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

80 Active assets in the Chronic Myeloproliferative Disorders cohort.

Asset / SponsorPhaseRating
Evomela
Center for International Blood and Marrow Transplant Research
Phase 2/3BBB
Fludarabine
Sawa Ito, MD
Phase 4BB
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2/3BB
Busulphan
Sawa Ito, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Ravuconazole is also rated in:

myelodysplastic/myeloproliferative neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
infectious diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
testicular germ cell tumorDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →